New drug cocktail aims to stop cervical cancer comeback after surgery
NCT ID NCT07466901
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two drugs (camrelizumab and famitinib) can help prevent cervical cancer from returning after surgery. It involves 30 women with specific cancer types and PD-L1 positive tumors. The main goal is to see how many patients remain cancer-free for two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Could a genetic marker guide future cancer therapies in taiwan?
- AI takes on cancer radiotherapy: can a computer plan treatment in minutes?
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
- Can acupuncture help women regain bladder control after hysterectomy?